ArticleCancer research2022
Aberrant Expression and Subcellular Localization of ECT2 Drives Colorectal Cancer Progression and Growth.
Open access · bronzeAbstract read
In one paragraph
Article in Cancer research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
3.3field-weighted citation impact, top 6% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 44 citations in OpenAlex.
- Early induction of the Rho-GEF ECT2 drives MEK/ERK oncogenic signaling in pancreatic ductal adenocarcinoma.Oncogene · 2026Article
- Ubiquitin-Specific Protease 2 (USP2) as a Modulator of Energy Metabolism: A Review of Studies Using Animal and Cellular Models.Biomedicines · 2026Review
- LSM4 as a potential prognostic indicator and therapeutic target in triple-negative breast cancer progression.Gland surgery · 2025Article
- Cytoplasmic anillin and Ect2 promote RhoA/myosin II-dependent confined migration and invasion.Nature materials · 2025Article
- Pan-Cancer Analysis of the Prognostic and Immunological Role of ECT2: A Promising Target for Survival and Immunotherapy.Cancer informatics · 2025Article
- Transcription factor ETS1‑mediated ECT2 expression promotes the malignant behavior of prostate cancer cells.Oncology letters · 2024Article
- New Mechanisms Underlying Oncogenesis in Dbl Family Rho Guanine Nucleotide Exchange Factors.Molecular pharmacology · 2024Review
- Article
- Sulfation of chondroitin and bile acids converges to antagonize Wnt/Acta pharmaceutica Sinica. B · 2024Article
- VAV2 orchestrates the interplay between regenerative proliferation and ribogenesis in both keratinocytes and oral squamous cell carcinoma.Scientific reports · 2024Article
- RBFOX2 deregulation promotes pancreatic cancer progression and metastasis through alternative splicing.Nature communications · 2023Article
- RHOAScience signaling · 2023Article
- TEAD Inhibition Overcomes YAP1/TAZ-Driven Primary and Acquired Resistance to KRASG12C Inhibitors.Cancer research · 2023Article
- Sulfoconjugation of protein peptides and glycoproteins in physiology and diseases.Pharmacology & therapeutics · 2023Review
- Identifying novel regulatory effects for clinically relevant genes through the study of the Greek population.BMC genomics · 2023Article
- Review
- Integration of Chemoinformatics and Multi-Omics Analysis Defines ECT2 as a Potential Target for Cancer Drug Therapy.Biology · 2023Article
- Cytokinesis machinery promotes cell dissociation from collectively migrating strands in confinement.Science advances · 2023Article
- Screening of four signature genes for clinical testing through bioinformatics and in vitro methods in head and neck squamous cell carcinoma.American journal of cancer research · 2023Article
- LAFITE Reveals the Complexity of Transcript Isoforms in Subcellular Fractions.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
25 authors at 5 institutions in 3 countries.
Danielle R CookDivision of Chemical Biology and Medicinal Chemistry, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.
Melissa KangCenter for Gastrointestinal Biology and Disease, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.
Timothy D MartinDepartment of Pharmacology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.ORCID 0000-0002-4870-3624
Joseph A GalankoCenter for Gastrointestinal Biology and Disease, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.
Gabriela H LoezaDepartment of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.
Dimitri G TrembathLineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.ORCID 0000-0001-5068-1017
Verline JustilienDepartment of Cancer Biology, Mayo Clinic Comprehensive Cancer Center, Jacksonville, Florida.ORCID 0000-0001-6378-3469
Karen A PickeringCancer Research UK Beatson Institute, Glasgow, United Kingdom.ORCID 0000-0002-6085-5276
David F VincentCancer Research UK Beatson Institute, Glasgow, United Kingdom.
Armin JaroschCharité Universitätsmedizin Berlin, Institute of Pathology, Laboratory of Molecular Tumor Pathology and Systems Biology, Berlin, Germany.
Philipp JurmeisterCharité Universitätsmedizin Berlin, Institute of Pathology, Laboratory of Molecular Tumor Pathology and Systems Biology, Berlin, Germany.
Andrew M WatersLineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.ORCID 0000-0002-6058-5878
Priya S HibshmanLineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.
Andrew D CampbellCancer Research UK Beatson Institute, Glasgow, United Kingdom.
Catriona A FordCancer Research UK Beatson Institute, Glasgow, United Kingdom.
Temitope O KekuCenter for Gastrointestinal Biology and Disease, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.
Jen Jen YehDepartment of Pharmacology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.
Michael S LeeDepartment of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.ORCID 0000-0001-8407-3423
Adrienne D CoxDepartment of Pharmacology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.ORCID 0000-0002-4901-2454
Alan P FieldsDepartment of Cancer Biology, Mayo Clinic Comprehensive Cancer Center, Jacksonville, Florida.
Robert S SandlerCenter for Gastrointestinal Biology and Disease, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.ORCID 0000-0002-1323-6245
Owen J SansomCancer Research UK Beatson Institute, Glasgow, United Kingdom.ORCID 0000-0001-9540-3010
Christine SersCharité Universitätsmedizin Berlin, Institute of Pathology, Laboratory of Molecular Tumor Pathology and Systems Biology, Berlin, Germany.ORCID 0000-0002-6219-1514
Antje SchaeferDepartment of Pharmacology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina. cjder@med.unc.edu antje_schaefer@med.unc.edu.ORCID 0000-0002-2716-9899
Channing J DerDivision of Chemical Biology and Medicinal Chemistry, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina. cjder@med.unc.edu antje_schaefer@med.unc.edu.
University of North Carolina at Chapel Hill · USCancer Research UK Scotland Institute · GBCancer Clinic · USInstitute of Molecular Biology · DEGerman Cancer Research Center · DE
Funding
PILOT AND FEASIBILITY STUDIESP30DK034987 · NIDDK · UNIV OF NORTH CAROLINA CHAPEL HILL · PI ROBERT S. SANDLER · 1985 to 2026
$30.5MThree-Dimensional Organoid Cultures to Investigate 3q26 Driver Functions in Multiple Lung Cancer Cells of OriginR01CA081436 · NCI · UNIVERSITY OF TEXAS MEDICAL BR GALVESTON · PI FIELDS, ALAN P. · 1999 to 2022
$9.9MVALIDATION OF INHIBITORS OF RHO GTPASES FOR CANCER TREATMENTU19CA067771 · NCI · UNIVERSITY OF SOUTH FLORIDA · PI GUIDA, WAYNE · 1995 to 2009
$8.9MCANCER CELL BIOLOGY TRAINING PROGRAMT32CA071341 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI CHANNING J. DER, Yuliya Pylayeva-Gupta · 1996 to 2026
$5.0MNC Colorectal Cancer Care Outcomes Research StudyU01CA093326 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI SANDLER, ROBERT S. · 2001 to 2008
$4.3MIdentification of synthetic lethal interactors in pancreatic cancerU01CA199235 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI COX, ADRIENNE D, DER, CHANNING J. · 2015 to 2019
$2.5MMechanism and role of DLC-1 tumor suppressor loss in lung cancerR01CA129610 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI DER, CHANNING J. · 2008 to 2012
$1.5MTargeting Ras-Ral GEF-Ral Effector Signaling for Pancreatic Cancer TreatmentR01CA140424 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI YEH, JEN JEN · 2010 to 2014
$1.5MAtypical PKC signaling in lung cancer stem cellsR21CA151250 · NCI · MAYO CLINIC JACKSONVILLE · PI FIELDS, ALAN P. · 2010 to 2011
$529kEct2 Function in Lung Adenocarcinoma Initiation and MaintenanceR21CA204938 · NCI · MAYO CLINIC JACKSONVILLE · PI JUSTILIEN, VERLINE · 2016 to 2017
$402kThe pathophysiology and palliation of the paclitaxel-induced acute pain syndromeR21CA180997 · NCI · MAYO CLINIC ROCHESTER · PI FIELDS, ALAN P., JATOI, AMINAH · 2014 to 2015
$365kElucidating the Molecular Mechanisms of Ect2 in cytokinesis and oncogenesisF31CA159821 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI COOK, DANIELLE RYAN · 2011 to 2012
$75kCancer Research UK 21139Cancer Research UK A21139NCI NIH HHS F31 CA159821NCI NIH HHS R01 CA081436NCI NIH HHS R01 CA129610NCI NIH HHS R01 CA140424NCI NIH HHS R21 CA151250NCI NIH HHS R21 CA180997NCI NIH HHS R21 CA204938NCI NIH HHS T32 CA071341NCI NIH HHS U01 CA093326NCI NIH HHS U01 CA199235NCI NIH HHS U19 CA067771NIDDK NIH HHS P30 DK034987
Abstract
ECT2 is an activator of RHO GTPases that is essential for cytokinesis. In addition, ECT2 was identified as an oncoprotein when expressed ectopically in NIH/3T3 fibroblasts. However, oncogenic activation of ECT2 resulted from N-terminal truncation, and such truncated ECT2 proteins have not been found in patients with cancer. In this study, we observed elevated expression of full-length ECT2 protein in preneoplastic colon adenomas, driven by increased
Indexed as
AgedAnimalsColorectal NeoplasmsDisease Models, AnimalDisease ProgressionFemaleGenomicsHumansMaleMiceProto-Oncogene ProteinsEct2 protein, mouseProto-Oncogene Proteins
Identifiers
What Socratic holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.